Artelo Biosciences (NASDAQ:ARTL) Issues Earnings Results

Artelo Biosciences (NASDAQ:ARTL) posted its quarterly earnings data on Wednesday. The company reported ($3.97) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($3.15), FiscalAI reports.

Artelo Biosciences Stock Performance

Shares of ARTL opened at $1.83 on Thursday. Artelo Biosciences has a 1 year low of $1.66 and a 1 year high of $28.60. The stock has a 50-day simple moving average of $4.15 and a 200-day simple moving average of $7.51. The stock has a market capitalization of $1.28 million, a PE ratio of -0.10 and a beta of 1.23.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on ARTL shares. D. Boral Capital reaffirmed a “hold” rating on shares of Artelo Biosciences in a research note on Monday, September 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of Artelo Biosciences in a research note on Tuesday. D Boral Capital lowered Artelo Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Monday, September 8th. Finally, Wall Street Zen lowered Artelo Biosciences to a “strong sell” rating in a report on Saturday, August 9th. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $24.00.

Artelo Biosciences Company Profile

Artelo Biosciences, Inc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders.